282 related articles for article (PubMed ID: 7831504)
1. [How to assess the size of a clinical trial?].
Paesmans M
Rev Mal Respir; 1994; 11(6):547-57. PubMed ID: 7831504
[TBL] [Abstract][Full Text] [Related]
2. Optimal choice of the number of treatments to be included in a clinical trial.
Stallard N; Posch M; Friede T; Koenig F; Brannath W
Stat Med; 2009 Apr; 28(9):1321-38. PubMed ID: 19243083
[TBL] [Abstract][Full Text] [Related]
3. Optimal conditional error functions for the control of conditional power.
Brannath W; Bauer P
Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
[TBL] [Abstract][Full Text] [Related]
4. Predictive probability early termination plans for phase II clinical trials.
Herson J
Biometrics; 1979 Dec; 35(4):775-83. PubMed ID: 526523
[TBL] [Abstract][Full Text] [Related]
5. A composite design for transition from a preliminary to a full-scale study.
Lachin JM; Younes N
Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245
[TBL] [Abstract][Full Text] [Related]
6. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
7. Comparison of four sequential methods allowing for early stopping of comparative clinical trials.
Sebille V; Bellissant E
Clin Sci (Lond); 2000 May; 98(5):569-78. PubMed ID: 10781388
[TBL] [Abstract][Full Text] [Related]
8. Effect of a misspecification of response rates on type I and type II errors, in a phase II Simon design.
Baey C; Le Deley MC
Eur J Cancer; 2011 Jul; 47(11):1647-52. PubMed ID: 21493059
[TBL] [Abstract][Full Text] [Related]
9. A three-outcome design for randomized comparative phase II clinical trials.
Hong S; Wang Y
Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879
[TBL] [Abstract][Full Text] [Related]
10. The value of information and optimal clinical trial design.
Willan AR; Pinto EM
Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
[TBL] [Abstract][Full Text] [Related]
11. Issues in designing flexible trials.
Posch M; Bauer P; Brannath W
Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412
[TBL] [Abstract][Full Text] [Related]
12. Conditional power calculations for clinical trials with historical controls.
Korn EL; Freidlin B
Stat Med; 2006 Sep; 25(17):2922-31. PubMed ID: 16479548
[TBL] [Abstract][Full Text] [Related]
13. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
Masaki N; Koyama T; Yoshimura I; Hamada C
J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
[TBL] [Abstract][Full Text] [Related]
14. Conservative sample size estimation in nonparametrics.
De Martini D
J Biopharm Stat; 2011 Jan; 21(1):24-41. PubMed ID: 21191852
[TBL] [Abstract][Full Text] [Related]
15. Basic statistics for clinicians: 1. Hypothesis testing.
Guyatt G; Jaeschke R; Heddle N; Cook D; Shannon H; Walter S
CMAJ; 1995 Jan; 152(1):27-32. PubMed ID: 7804919
[TBL] [Abstract][Full Text] [Related]
16. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
Sposto R; Gaynon PS
Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
[TBL] [Abstract][Full Text] [Related]
17. Stochastically curtailed phase II clinical trials.
Ayanlowo AO; Redden DT
Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
[TBL] [Abstract][Full Text] [Related]
18. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
19. Assessment of futility in clinical trials.
Snapinn S; Chen MG; Jiang Q; Koutsoukos T
Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
[TBL] [Abstract][Full Text] [Related]
20. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
